Predictive Oncology Inc. POAI Archives - Page 2 of 19

TuesdayJun 22, 2021 11:25 am

Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Partners with Cellevate for New Approach to Ovarian Cancer

Collaboration will use TumorGenesis’ expertise in cancer cell culture growth media in combination with Cellevate’s specialty in emerging field of nanofiber matrixes. Cutting-edge technology can help avoid mistakes in $2.6 billion process of bringing new drugs through FDA process. Coupling companies’ technology will give researchers ability to grow ovarian cancer tissues in 3D matrix support system with right media for right ovarian cancer cell types Getting a drug through the complete FDA process, from pre-clinical to approval, is an arduous and expensive task, although there are signs that approval rates are accelerating after years of decline. Companion diagnostics, new approaches…

WednesdayJun 02, 2021 1:22 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Building Strong Commercial Pipeline for Unique PeDAL(TM) Platform

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, continues to create value for a growing customer base through its subsidiaries. Researchers from one such subsidiary, Helomics, recently completed key sequencing milestones for ovarian cancer to help build its AI-driven models of the disease. “We are building a strong commercial pipeline for our unique Patient-cEntric Discovery by Active Learning (PeDAL)(TM), which we launched at the beginning of 2021,” POAI CEO J. Melville Engle was quoted in a recent article. “PeDAL brings together the key Helomics assets of real-world longitudinal data…

FridayMay 28, 2021 9:00 am

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Highlights, Q1 Financials Herald Bright Horizon for Company

POAI announced that total stockholders’ equity increased by nearly $33 million to $35.5 million Financial report notes net proceeds of $35.6 million from private placement, direct offering, warrant exercises Company subsidiaries reached several milestone achievements throughout the quarter. Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, reported its financial results for first quarter 2021, the period ending March 31, 2021 (https://ibn.fm/kUVwH). The company also released key business updates along with its financial numbers. “The combination of equity transactions and retirement of our outstanding debt has brought significant value to…

WednesdayMay 26, 2021 1:11 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Adds Insight, Strengthens Positioning Through Strategic Board Appointment

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently expanded its board of directors with the appointment of Dr. Christina Jenkins. Dr. Jenkins holds capital markets expertise coupled with health care experience through roles that span clinical medicine, venture capital, health plans, and health care systems. Her unique skillset, multivariate perspective and extensive experience have enabled her to create growth-optimizing strategies for health care providers while improving patients’ outcomes. A recent article discussing the appointment quoted POAI CEO J. Melville Engle as saying, “We are very fortunate to have…

TuesdayMay 18, 2021 3:13 pm

QualityStocksNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics CTO Discusses Revolutionizing Drug Discovery in Bell2Bell Podcast

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in a recent episode of The Bell2Bell Podcast. Predictive Oncology’s newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, joined the program to share financial updates, future goals and insight into current operations. The discussion also highlighted Helomics’ innovative PeDAL (patient-centric drug discovery using active learning) platform. A unique technology, PeDAL combines a proprietary, clinically validated patient tumor cell line assay with a vast knowledge base of proprietary and…

TuesdayMay 18, 2021 1:31 pm

Predictive Oncology Inc. (NASDAQ: POAI) Appoints Venture Investor Dr. Christina Jenkins to Board of Directors

POAI appoints strategic advisor, venture investor Dr. Christina Jenkins to board of directors Dr. Jenkins’ experience spans work in capital markets, clinical medicine, public healthcare systems Other roles include current Board Director for Independence Health Group, Venture Partner at Phoenix Venture Partners, Board Observer for Madorra Inc., board advisory roles at multiple value-generating healthcare companies Past experience includes role as founding CEO of OneCity Health Services, subsidiary of NYC Health + Hospitals Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently appointed strategic advisor and venture investor Dr. Christina…

TuesdayMay 11, 2021 2:12 pm

Predictive Oncology’s (NASDAQ: POAI) C-Level Leaders Provide Company, Operations Update on New Podcast

Bell2Bell podcast features company CEO, CFO, CTO of Helomics subsidiary POAI is “in probably the best situation we’ve been in since the existence of the company,” reports CFO Company anticipates revenue from its unique PeDAL platform Three Predictive Oncology (NASDAQ: POAI) executives were featured guests on a recent Bell2Bell podcast (https://ibn.fm/DumLs). Newly appointed CEO Mel Engle, CFO Bob Myers and Mark Collins, chief technical officer of the company’s Helomics subsidiary, shared updates regarding POAI’s financial footing, current operations and goals for 2021 during the podcast, which delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Named Predictive…

ThursdayMay 06, 2021 3:04 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Advancing Solutions for ‘Personalized Medicine at Its Finest’

Predictive Oncology (NASDAQ: POAI) has made several advances in providing cancer treatment solutions. Its subsidiary, TumorGenesis, “specializes in technology that preserves a patient’s unique cancer tissue biological signatures, thereby allowing researchers to study cancer in the laboratory using samples that reflect actual tumors found in a patient,” reads a recent article. TumorGenesis’ transformational technology enables cell lines from patients to represent more than 90% of ovarian cancer cells, a significant improvement from the existing technologies, which can only represent 1% of ovarian tumor cells. “The result, simply stated, assists health providers in selecting the most effective drug to treat a…

TuesdayApr 27, 2021 3:08 pm

QualityStocksNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Featured in DojoLIVE! Interview

Predictive Oncology’s (NASDAQ: POAI) subsidiary company, Helomics, was recently featured on DojoLIVE!, an engaging podcast and interview forum that brings together technology, business and thought leaders from a wide range of industries. The company’s Chief Technical Officer, Mark Collins, PhD, joined the interview to discuss what Helomics is bringing to the table in the field of cancer research in the podcast titled “Can We Cure Cancer with Artificial Intelligence?” “At Helomics, we have a nice convergence of data that we’ve gathered from testing live tumors, tumors outside the patient body, on drugs, standard of care drugs, normal drugs that you…

WednesdayApr 21, 2021 2:04 pm

QualityStocksNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Featured in Bell2Bell Podcast

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, was featured in The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. Predictive Oncology’s newly appointed CEO, Mel Engle, its CFO, Bob Myers, and CTO of its Helomics subsidiary, Mark Collins, joined the latest episode to discuss updates on POAI’s financial footing, current operations and goals for 2021. “We are in a great situation, probably the best situation that we’ve been in since the existence of the company in terms of…

Site Search

Company Search

Tag: Predictive Oncology Inc. POAI